{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T05:12:32Z","timestamp":1792645952883,"version":"4.5.0"},"reference-count":99,"publisher":"Society of Nuclear Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.2967\/jnumed.120.256271","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T02:15:26Z","timestamp":1607134526000},"page":"296-302","source":"Crossref","is-referenced-by-count":126,"title":["FAPI PET\/CT: Will It End the Hegemony of <sup>18<\/sup>F-FDG in Oncology?"],"prefix":"10.2967","volume":"62","author":[{"given":"Rodney J.","family":"Hicks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Roselt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumarswamy G.","family":"Kallur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W.","family":"Tothill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Mileshkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2020,12,4]]},"reference":[{"key":"2021030407200935000_62.3.296.1","first-page":"52","article-title":"Epileptic patterns of local cerebral metabolism and perfusion in man: investigation by emission computed tomography of 18F-fluorodeoxyglucose and 13N-ammonia","volume":"103","author":"Kuhl","year":"1978","journal-title":"Trans Am Neurol Assoc."},{"key":"2021030407200935000_62.3.296.2","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.1982.15"},{"key":"2021030407200935000_62.3.296.3","first-page":"183","article-title":"Positron tomography of the heart","volume":"6","author":"Phelps","year":"1980","journal-title":"Prog Nucl Med."},{"key":"2021030407200935000_62.3.296.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-2998(97)80042-6"},{"key":"2021030407200935000_62.3.296.5","first-page":"1369","article-title":"A combined PET\/CT scanner for clinical oncology","volume":"41","author":"Beyer","year":"2000","journal-title":"J Nucl Med."},{"key":"2021030407200935000_62.3.296.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70141-3"},{"key":"2021030407200935000_62.3.296.7","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-09-0078"},{"key":"2021030407200935000_62.3.296.8","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet."},{"key":"2021030407200935000_62.3.296.9","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1007\/s00259-017-3670-z","article-title":"Ga-PSMA PET\/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0","volume":"44","author":"Fendler","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2021030407200935000_62.3.296.10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000475526","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues","volume":"105","author":"Hicks","year":"2017","journal-title":"Neuroendocrinology."},{"key":"2021030407200935000_62.3.296.11","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1007\/s00259-019-04485-3","article-title":"EANM procedure guidelines for radionuclide therapy with 177Lu-labeled PSMA-ligands (177Lu-PSMA-RLT)","volume":"46","author":"Kratochwil","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2021030407200935000_62.3.296.12","first-page":"vdz010","article-title":"Current status of PET imaging in neuro-oncology","volume":"1","author":"Galldiks","year":"2019","journal-title":"Neurooncol Adv."},{"key":"2021030407200935000_62.3.296.13","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2012.188"},{"key":"2021030407200935000_62.3.296.14","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","article-title":"The tumour microenvironment in pancreatic cancer: clinical challenges and opportunities","volume":"17","author":"Ho","year":"2020","journal-title":"Nat Rev Clin Oncol."},{"key":"2021030407200935000_62.3.296.15","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.73"},{"key":"2021030407200935000_62.3.296.16","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-018-0004-1"},{"key":"2021030407200935000_62.3.296.17","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1353"},{"key":"2021030407200935000_62.3.296.18","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0238-1"},{"key":"2021030407200935000_62.3.296.19","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41575-019-0115-0","article-title":"Cancer associated fibroblasts in gastrointestinal cancer","volume":"16","author":"Kobayashi","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"2021030407200935000_62.3.296.20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12943-019-0994-2","article-title":"Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance","volume":"18","author":"Fiori","year":"2019","journal-title":"Mol Cancer."},{"key":"2021030407200935000_62.3.296.21","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1384"},{"key":"2021030407200935000_62.3.296.22","doi-asserted-by":"publisher","DOI":"10.1038\/nri2808"},{"key":"2021030407200935000_62.3.296.23","doi-asserted-by":"crossref","first-page":"6129\u20136137","DOI":"10.1038\/s41388-020-01424-7","article-title":"Cancer-associated fibroblasts downregulate type I interferon receptor to stimulate intratumoral stromagenesis","volume":"39","author":"Cho","year":"2020","journal-title":"Oncogene."},{"key":"2021030407200935000_62.3.296.24","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ccell.2020.05.001","article-title":"MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate","volume":"38","author":"Ireland","year":"2020","journal-title":"Cancer Cell."},{"key":"2021030407200935000_62.3.296.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.05.040"},{"key":"2021030407200935000_62.3.296.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpj.2014.10.035"},{"key":"2021030407200935000_62.3.296.27","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0094"},{"key":"2021030407200935000_62.3.296.28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.12.5657"},{"key":"2021030407200935000_62.3.296.29","doi-asserted-by":"crossref","first-page":"140409","DOI":"10.1016\/j.bbapap.2020.140409","article-title":"Molecular recognition of fibroblast activation protein for diagnostic and therapeutic applications","volume":"1868","author":"\u0160imkov\u00e1","year":"2020","journal-title":"Biochim Biophys Acta Proteins Proteomics."},{"key":"2021030407200935000_62.3.296.30","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.51.36505"},{"key":"2021030407200935000_62.3.296.31","doi-asserted-by":"publisher","DOI":"10.1126\/science.1195300"},{"key":"2021030407200935000_62.3.296.32","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0150"},{"key":"2021030407200935000_62.3.296.33","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.neo.2019.10.005","article-title":"Fibroblastic FAP promotes intrahepatic cholangiocarcinoma growth via MDSCs recruitment","volume":"21","author":"Lin","year":"2019","journal-title":"Neoplasia."},{"key":"2021030407200935000_62.3.296.34","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1320318110"},{"key":"2021030407200935000_62.3.296.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2005.02.034"},{"key":"2021030407200935000_62.3.296.36","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3389\/fonc.2020.00979","article-title":"High expression of FAP in colorectal cancer is associated with angiogenesis and immunoregulation processes","volume":"10","author":"Coto-Llerena","year":"2020","journal-title":"Front Oncol."},{"key":"2021030407200935000_62.3.296.37","doi-asserted-by":"crossref","first-page":"13961","DOI":"10.1007\/s13277-016-5274-9","article-title":"Fibroblast activation protein alpha is expressed by transformed and stromal cells and is associated with mesenchymal features in glioblastoma","volume":"37","author":"Busek","year":"2016","journal-title":"Tumour Biol."},{"key":"2021030407200935000_62.3.296.38","doi-asserted-by":"crossref","first-page":"109021","DOI":"10.1016\/j.ejrad.2020.109021","article-title":"FAP-specific PET signaling shows a moderately positive correlation with relative CBV and no correlation with ADC in 13 IDH wildtype glioblastomas","volume":"127","author":"R\u00f6hrich","year":"2020","journal-title":"Eur J Radiol."},{"key":"2021030407200935000_62.3.296.39","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1055\/s-0037-1613388","article-title":"Endothelial cell serine proteases expressed during vascular morphogenesis and angiogenesis","volume":"89","author":"Aimes","year":"2003","journal-title":"Thromb Haemost."},{"key":"2021030407200935000_62.3.296.40","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2009.03399.x"},{"key":"2021030407200935000_62.3.296.41","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e31816618ce"},{"key":"2021030407200935000_62.3.296.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2011.01.011"},{"key":"2021030407200935000_62.3.296.43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s12307-014-0153-7","article-title":"Stromal expression of fibroblast activation protein alpha (FAP) predicts platinum resistance and shorter recurrence in patients with epithelial ovarian cancer","volume":"8","author":"Mhawech-Fauceglia","year":"2015","journal-title":"Cancer Microenviron."},{"key":"2021030407200935000_62.3.296.44","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-012-0638-2"},{"key":"2021030407200935000_62.3.296.45","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3041"},{"key":"2021030407200935000_62.3.296.46","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-5211"},{"key":"2021030407200935000_62.3.296.47","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.18.7235"},{"key":"2021030407200935000_62.3.296.48","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.1994.12.6.1193","article-title":"Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts","volume":"12","author":"Welt","year":"1994","journal-title":"J Clin Oncol."},{"key":"2021030407200935000_62.3.296.49","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.4.1556"},{"key":"2021030407200935000_62.3.296.50","doi-asserted-by":"publisher","DOI":"10.1021\/jm1002556"},{"key":"2021030407200935000_62.3.296.51","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1021\/ml300410d","article-title":"Selective inhibitors of fibroblast activation protein (FAP) with a (4-quinolinoyl)-glycyl-2-cyanopyrrolidine scaffold","volume":"4","author":"Jansen","year":"2013","journal-title":"ACS Med Chem Lett."},{"key":"2021030407200935000_62.3.296.52","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.210435"},{"key":"2021030407200935000_62.3.296.53","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.224469"},{"key":"2021030407200935000_62.3.296.54","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.210443"},{"key":"2021030407200935000_62.3.296.55","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.215913"},{"key":"2021030407200935000_62.3.296.56","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.227967"},{"key":"2021030407200935000_62.3.296.57","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1007\/s00259-019-04478-2","article-title":"IgG4-related disease revealed by 68Ga-FAPI and 18F-FDG PET\/CT","volume":"46","author":"Luo","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2021030407200935000_62.3.296.58","unstructured":"Chen H Zhao L Ruan D . Usefulness of 68Ga-FAPI and 18F-FDG PET\/CT in a patient with cholangiocellular carcinoma. Eur J Nucl Med Mol Imaging. June 25, 2020 [Epub ahead of print]."},{"key":"2021030407200935000_62.3.296.59","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1007\/s00259-020-04769-z","article-title":"Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET\/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer","volume":"47","author":"Chen","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2021030407200935000_62.3.296.60","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1007\/s00259-020-04859-y","article-title":"Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers","volume":"47","author":"Syed","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2021030407200935000_62.3.296.61","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.248823"},{"key":"2021030407200935000_62.3.296.62","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.236786"},{"key":"2021030407200935000_62.3.296.63","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2967\/jnumed.119.237016","article-title":"The role of FAPI-PET\/CT for patients with malignancies of the lower gastrointestinal tract: first clinical experience","volume":"61","author":"Koerber","year":"2020","journal-title":"J Nucl Med."},{"key":"2021030407200935000_62.3.296.64","doi-asserted-by":"crossref","unstructured":"Giesel F Adeberg S Syed M . FAPI-74 PET\/CT using either 18F-AlF or cold-kit 68Ga-labeling: biodistribution, radiation dosimetry and tumor delineation in lung cancer. J Nucl Med. June 26, 2020 [Epub ahead of print].","DOI":"10.2967\/jnumed.120.245084"},{"key":"2021030407200935000_62.3.296.65","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.242958"},{"key":"2021030407200935000_62.3.296.66","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1007\/s00259-019-04346-z","article-title":"FAPI-PET\/CT improves staging in a lung cancer patient with cerebral metastasis","volume":"46","author":"Giesel","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2021030407200935000_62.3.296.67","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/RLU.0000000000003231","article-title":"68Ga-FAPI PET\/CT in assessment of leptomeningeal metastases in a patient with lung adenocarcinoma","volume":"45","author":"Hao","year":"2020","journal-title":"Clin Nucl Med."},{"key":"2021030407200935000_62.3.296.68","doi-asserted-by":"crossref","unstructured":"Hao B Wu X Pang Y . [18F]FDG and [68Ga]Ga-DOTA-FAPI-04 PET\/CT in the evaluation of tuberculous lesions. Eur J Nucl Med Mol Imaging. July 8, 2020 [Epub ahead of print].","DOI":"10.1007\/s00259-020-04941-5"},{"key":"2021030407200935000_62.3.296.69","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.radonc.2020.06.040","article-title":"Fibroblast activation protein (FAP) specific PET for advanced target volume delineation in glioblastoma","volume":"150","author":"Windisch","year":"2020","journal-title":"Radiother Oncol."},{"key":"2021030407200935000_62.3.296.70","doi-asserted-by":"crossref","first-page":"6208\u20136218","DOI":"10.1158\/1078-0432.CCR-12-0644","article-title":"Radioimmunotherapy of fibroblast activation protein positive tumors by rapidly internalizing antibodies","volume":"18","author":"Fischer","year":"2012","journal-title":"Clin Cancer Res."},{"key":"2021030407200935000_62.3.296.71","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.233122"},{"key":"2021030407200935000_62.3.296.72","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.217745"},{"key":"2021030407200935000_62.3.296.73","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.182188"},{"key":"2021030407200935000_62.3.296.74","doi-asserted-by":"crossref","first-page":"1386\u20131396","DOI":"10.1039\/C3DT52647J","article-title":"PET imaging of tumours with a 64Cu labeled macrobicyclic cage amine ligand tethered to Tyr3-octreotate","volume":"43","author":"Paterson","year":"2014","journal-title":"Dalton Trans."},{"key":"2021030407200935000_62.3.296.75","first-page":"1639","article-title":"A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer","volume":"9","author":"Scott","year":"2003","journal-title":"Clin Cancer Res."},{"key":"2021030407200935000_62.3.296.76","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1038\/s41388-018-0275-3","article-title":"Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics","volume":"37","author":"Pur\u00e9","year":"2018","journal-title":"Oncogene."},{"key":"2021030407200935000_62.3.296.77","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.9.3110"},{"key":"2021030407200935000_62.3.296.78","doi-asserted-by":"publisher","DOI":"10.1007\/BF02147594"},{"key":"2021030407200935000_62.3.296.79","doi-asserted-by":"publisher","DOI":"10.1186\/ar2080"},{"key":"2021030407200935000_62.3.296.80","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.152959"},{"key":"2021030407200935000_62.3.296.81","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s00259-019-04388-3","article-title":"PET-detected pneumonitis following curative-intent chemoradiation in non-small cell lung cancer (NSCLC): recognizing patterns and assessing the impact on the predictive ability of FDG-PET\/CT response assessment","volume":"46","author":"Iravani","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2021030407200935000_62.3.296.82","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.04.021"},{"key":"2021030407200935000_62.3.296.83","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejphar.2017.05.022","article-title":"Effects of the fibroblast activation protein inhibitor, PT100, in a murine model of pulmonary fibrosis","volume":"809","author":"Egger","year":"2017","journal-title":"Eur J Pharmacol."},{"key":"2021030407200935000_62.3.296.84","doi-asserted-by":"crossref","first-page":"254\u2013256","DOI":"10.1038\/335254a0","article-title":"Serotonin stimulates DNA synthesis in fibroblasts acting through 5-HT1B receptors coupled to a Gi-protein","volume":"335","author":"Seuwen","year":"1988","journal-title":"Nature."},{"key":"2021030407200935000_62.3.296.85","first-page":"71","article-title":"Involvement of transforming growth factor-\u03b2 in the formation of fibrotic lesions in carcinoid heart disease","volume":"142","author":"Waltenberger","year":"1993","journal-title":"Am J Pathol."},{"key":"2021030407200935000_62.3.296.86","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-09790-1"},{"key":"2021030407200935000_62.3.296.87","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2015.08.016"},{"key":"2021030407200935000_62.3.296.88","doi-asserted-by":"crossref","first-page":"e010628","DOI":"10.1161\/CIRCIMAGING.120.010628","article-title":"Relationship between cardiac fibroblast activation protein activity by positron emission tomography and cardiovascular disease","volume":"13","author":"Heckmann","year":"2020","journal-title":"Circ Cardiovasc Imaging."},{"key":"2021030407200935000_62.3.296.89","doi-asserted-by":"crossref","unstructured":"Siebermair J K\u00f6hler MI Kupusovic J . Cardiac fibroblast activation detected by Ga-68 FAPI PET imaging as a potential novel biomarker of cardiac injury\/remodeling. J Nucl Cardiol. September 25, 2020 [Epub ahead of print].","DOI":"10.1007\/s12350-020-02307-w"},{"key":"2021030407200935000_62.3.296.90","doi-asserted-by":"crossref","first-page":"e430","DOI":"10.1097\/RLU.0000000000003015","article-title":"68Ga-FAPI PET\/CT in assessment of liver nodules in a cirrhotic patient","volume":"45","author":"Zhao","year":"2020","journal-title":"Clin Nucl Med."},{"key":"2021030407200935000_62.3.296.91","doi-asserted-by":"crossref","unstructured":"Shi X Xing H Yang X . Fibroblast imaging of hepatic carcinoma with 68Ga-FAPI04 PET\/CT: a pilot study in patients with suspected hepatic nodules. Eur J Nucl Med Mol Imaging. May 29, 2020 [Epub ahead of print].","DOI":"10.1007\/s00259-020-04882-z"},{"key":"2021030407200935000_62.3.296.92","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/RLU.0000000000002919","article-title":"Recurrent immunoglobulin G4-related disease shown on 18F-FDG and 68Ga-FAPI PET\/CT","volume":"45","author":"Pan","year":"2020","journal-title":"Clin Nucl Med."},{"key":"2021030407200935000_62.3.296.93","doi-asserted-by":"crossref","unstructured":"Luo Y Pan Q Yang H Peng L Zhang W Li F . Fibroblast activation protein targeted PET\/CT with 68Ga-FAPI for imaging IgG4-related disease: comparison to 18F-FDG PET\/CT. J Nucl Med. June 8, 2020 [Epub ahead of print].","DOI":"10.2967\/jnumed.120.244723"},{"key":"2021030407200935000_62.3.296.94","doi-asserted-by":"crossref","first-page":"1460\u20131471","DOI":"10.1016\/S0140-6736(14)60720-0","article-title":"IgG4-related disease","volume":"385","author":"Kamisawa","year":"2015","journal-title":"Lancet."},{"key":"2021030407200935000_62.3.296.95","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.3390\/molecules20022081","article-title":"Evaluation of the radiolabeled boronic acid-based FAP inhibitor MIP-1232 for atherosclerotic plaque imaging","volume":"20","author":"Meletta","year":"2015","journal-title":"Molecules."},{"key":"2021030407200935000_62.3.296.96","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.3390\/cancers12092629","article-title":"Clinical results of fibroblast activation protein (FAP) specific PET and implications for radiotherapy planning: systematic review","volume":"12","author":"Windisch","year":"2020","journal-title":"Cancers (Basel)."},{"key":"2021030407200935000_62.3.296.97","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.239731"},{"key":"2021030407200935000_62.3.296.98","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3389\/fmed.2019.00132","article-title":"Rhenium-188 labeled radiopharmaceuticals: current clinical applications in oncology and promising perspectives","volume":"6","author":"Lepareur","year":"2019","journal-title":"Front Med (Lausanne)."},{"key":"2021030407200935000_62.3.296.99","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0095"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.120.256271","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T15:24:35Z","timestamp":1614871475000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.120.256271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":99,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,2,23]]},"published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.2967\/jnumed.120.256271"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.120.256271","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,4]]}}}